Composition for treatment of articular cartilage damage
AssigneesMedipost Co., Ltd., Chul-Won Ha
InventorsChul-Won Ha, Yoon-Sun Yang, Sung-Eun Yang
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a composition for the treatment of articular cartilage damage or loss or defect. The composition for the treatment of articular cartilage injury of the present invention includes (i) cellular components separated, proliferated, and/or differentiated from the umbilical cord blood, (ii) a culture medium; and (iii) a biocompatible polymer. The composition has very superior ability of proliferation and differentiation and easier to be collected and acquired.
Claims33
A composition for the treatment of articular cartilage damage, loss, or defect, said composition comprising mesenchymal stem cells isolated from umbilical cord blood, a culture medium, and a biocompatible polymer,
- wherein said composition treats articular cartilage damage, loss, or defect when administered to a site of articular cartilage damage, loss, or defect in a subject.
A composition for the treatment of articular cartilage damage, loss, or defect, said composition comprising mesenchymal stem cells isolated from umbilical cord blood, a culture medium, and a biocompatible polymer,
- wherein the composition contains 1×106 to 5×107 cells per mL of the composition;
- wherein the biocompatible polymer is hyaluronic acid in a final concentration of 0.5% -4% by weight based on the total volume of the composition;
- and
- wherein said composition treats articular cartilage damage, loss, or defect when administered to a site of articular cartilage damage, loss, or defect in a subject.
Dependencies are inferred from the claim text.